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Abstract
Objectives: This study aims to compare the 2017-ACC/AHA hypertension guideline with 2014-JNC-8 guideline in regard to the number of patients who are eligible for treatment and to determine the physicians’ adherence and the
ﬁnancial impact of implementing the new guideline.
Methods: A cross-sectional observational study was conducted on adult patients who attended the hospital outpatient
setting in UAE during January 1, 2018 till February 28, 2018. Adults who are diagnosed with hypertension and those with
blood pressure (BP) levels based on two or more readings obtained on two or more different occasions were screened for
inclusion into this study and cardiovascular diseases (CVD) risk was calculated. The two guidelines were compared with
respect to the number of patients diagnosed with hypertension and eligible for treatment. Results were extrapolated to
the UAE population. Financial impact of applying the 2017-ACC/AHA guideline was also evaluated.
Results: In comparison with the JNC-8, the 2017-ACC/AHA guideline would increase the proportion of patients
diagnosed with hypertension among UAE adults from 40.8% to 76.3% and the number of UAE adults recommended for
antihypertensive medications would rise from 2.42 million (32.1%) to 4.71 million (62.5%). Among UAE adults, almost
4.42 million (58.6%) and 0.76 million (10.1%) would have BP above the target according to the 2017-ACC/AHA and JNC-8
guidelines, respectively. The expected increase in the cost of anti-hypertension medications prescribed for the new
labeled cases according to 2017-ACC/AHA but not JNC-8 would reach 1.8 billion AED/year. For those who were recommended for antihypertensive medications, who had BP above target, the additional cost would reach 3.5 billion AED/
year.
Conclusions: The current study reveals marked increase in the proportion of patients diagnosed with hypertension in
concordance with the 2017-ACC/AHA guideline. This is also will be associated with almost double the number of UAE
adults recommended for antihypertensive medications. The poor compliance with the 2017-ACC/AHA reﬂects the
concern regarding the increase risk of adverse events.
Keywords: Hypertension, ACC/AHA (American College of Cardiology / American Heart Association) guideline, JNC 8
(The Eighth Joint National Committee) guideline

1. Introduction

U

ntil recently, the guideline of the eighth joint
national committee (JNC-8) was the

recommended guideline for the management of
hypertension [1]. In 2017, the ACC/AHA and 9
other specialty organizations published an updated hypertension guideline that contains new
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deﬁnition of the blood pressure level targets
which is lower than the previous guidelines and
many other changes. Consequently, increased the
number of candidates people for monitoring and
treatment [2,3].
As a matter of fact, the number of hypertensive
patients who are already treated with antihypertensive drugs will require more aggressive treatment to bring their BP level to the target.
Subsequently, many patients should receive combinations or poly-therapy that lead to potentially
use expensive antihypertensive drugs. Accordingly,
the incidence of adverse events will likely to be
increased with such treatment regimen [3,4]. Based
on several clinical trials, adverse events were more
common and more serious with intensive therapy.
These include hypotension, acute renal failure,
syncope and electrolyte disturbance that may cause
loss of beneﬁt of treatment and discontinuation of
therapy [5e9].
The main study question is whether the new
recommendations are feasible in clinical practice?
For that reason, this study had been conducted to
compare the 2017-ACC/AHA guideline with the
most recent JNC Guideline (JNC-8, 2014) [1,4] with
regard to the number of patients who are eligible for
treatment with antihypertensive and to determine
the ﬁnancial impact of implementing the new
guideline. Adherence of physicians to the new
guideline was also examined.

2. Methodology
2.1. Subjects
A cross-sectional observational study of adult
patients who visited a hospital outpatient setting
(internal medicine and Cardiology clinics) in United
Arab Emirates (UAE) during January 1, 2018 till
February 28, 2018 (n ¼ 1196). Patients’ information
had been collected through Hospital Information
System (HIS). Adults who are already diagnosed
with hypertension (as documented in HIS) and also
adults with two or more blood pressure reading
obtained on two or more different occasions were
included in this study. Tourists were excluded, as
they do not represent UAE population. CVD risk
was calculated using the Pooled Cohort Risk Equation [10].
The analysis was restricted to those who were
aged 18 years old and older and met the criteria of
enrollment (n ¼ 400, 33.4%). Participants who didn't
meet the inclusion criteria were excluded (n ¼ 796).
Reasons for exclusion were: two or more BP
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readings on two or more different occasions were
not available (n ¼ 568) and patient who were tourists
(n ¼ 228).
This study was approved by the Research Ethics
Committee of the hospital (CR/2018/27).

2.2. Statistical analysis
All data were entered and analyzed using SPSS
version 22 (IBM SPSS Statistics for Windows,
Version 24.0. Armonk, NY: IBM Corp.). Descriptive
statistics were used for measuring the frequencies
and percentages. Chi-square test was used to
compare the frequencies. A p value of 0.05 was
considered statistically signiﬁcant, using 95.0%
conﬁdence interval of differences.
The following outcomes were investigated in this
study:
A. The two guidelines were compared with regard
to the following:
1. The proportions of patients were compared
for whom antihypertensive therapies would
be recommended (i.e., eligible persons) on
the basis of the two sets of guidelines.
2. The proportions of patients who had abovegoal BP according to the two sets of
guidelines were also recorded and
compared.
B. Cost Implication of Applying the 2017-ACC/
AHA Guideline
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Table 1. Estimation of the cost an additional antihypertensive medication prescribed in United Arab Emirates Dirhams.
No of antihypertension
drug classes used

No. of patients

1
66 (38.8%)
2
50 (29.4%)
3
32 (18.8%)
4
22 (13%)
Total
170 (100%)
Mean value of the cost of each additional antihypertensive drug ¼
a

Medication cost/
patient/montha

Cost of additional drug
cost/patient/month

65.6 ± 34.4 AED
125.2 ± 35.6 AED
199.9 ± 64.6 AED
269.3 ± 50.8 AED
134.7 ± 83.4 AED

65.6 AED
62.6 AED
66.6 AED
67.3 AED
262.1 AED
65.5 ± 2.07 AED

Mean value of the estimated medications cost for each patient per month. AED: United Arab Emirates Dirham.

The additional cost of hypertension treatment due
to the expanding of disease deﬁnition “according to
the 2017-ACC/AHA guideline” was estimated by
calculating the average cost of one antihypertensive
medication for the study patients based on the UAE
average market value. Table 1 also illustrates how
we calculated the average cost of adding one
medication for each patient per month.
According to Table 1 the average cost of an
additional antihypertensive medication would be
nearly 65.5 United Arab Emirates Dirham (AED) per
month per medication (786 AED per year). Table 2
illustrates the list of antihypertensive medications
used during the study and their cost.
C. The results were extrapolated to produce UAE
population estimates and the ﬁnancial impact of
applying the 2017-ACC/AHA guideline on the
whole population was also evaluated. The
extrapolation of this study data to the 7.54
million UAE adults between the ages of 18 and
75 years based on the National Epidemiological
Study of Hypertension in the United Arab
Emirates (NESH-UAE), Dubai Heart Center survey report 2014 - Dubai Health Authority
(DHA) and UAE National Bureau of statistics of
UAE population [11e15]. Of whom, 40.8%
(n ¼ 3.07 million UAE adults) had history of
hypertension based on the 2014 JNC-8 guideline.
D. Adherence of physicians to the new guideline was
determined by determining the percentage of patients who were receiving treatment based on the
2017-ACC/AHA guideline recommendations.

3. Results
3.1. Demographic and clinical characteristics of the
study sample
Demographic and clinical characteristics of the
study sample are shown in Tables 3 and 4. Out of all
subjects, there were 238 male patients (59.5%-mean
age 49 years, SD ¼ 10) and 162 female patients
(40.5%-mean age 50 years, SD ¼ 13). Out of those

with history of any disease (80%-320 patients), 206
patients (51.5%) were diagnosed with hypertension,
196 patients (49%) had diabetes mellitus and 172
patients (43%) had dyslipidemia. Nevertheless, from
those who had history of hypertension, only 170
patients (82.5%; 114 males and 56 females) were on
antihypertensive medications. Of whom, 66 patients
(32%; 38 males and 28 females) were on one class of
antihypertensive medication, 50 patients (24.3%; 34
males and 16 females) were on two classes of antihypertensive medications and 54 patients (26.2%; 42
males and 12 females) were on three or more classes
of antihypertensive medications. Whereas, 36 patients (17.5%; 18 males and 18 females) were on nonpharmacological intervention for treatment of
hypertension.
Additionally, 52 patients (13%; 38 males and 14
females) had history of clinical atherosclerosis cardiovascular disease (ASCVD). Out of all participants
without history of clinical ASCVD, 140 participants
(35%; 38 males and 102 females) had estimated 10
years CVD risk less than 5%, 72 participants (18%; 54
males and 18 females) had estimated 10 years CVD
risk between 5% and less than 10% and 136 participants (34%; 108 males and 28 females) had estimated
10 years CVD risk equal to or more than 10%.
3.2. The proportions of patients for whom
antihypertensive therapies would be recommended
The number of patients with hypertension were
increased to 358 (89.5%) according to ACC/AHA
guideline as compared to 216 (54%) according to
JNC-8 guideline which represented a 65.7% increase
in patients who were categorized as hypertensive
patients (Table 5). There is a signiﬁcant increase in
number of hypertensive patients implementing
ACC/AHA guideline X2(df ¼ 1) ¼ 124.3, p < 0.0001.
According to JNC-8 guideline 108 (27%) patients
were labeled as stage 1 hypertension and require
mono-therapy with an antihypertensive medication.
In comparison, according to the 2017-ACC/AHA
guideline, 244 (61%) patients were labeled as stage 1
hypertension and advised to be treated either with

Table 2. List of antihypertensive medications used during the study.
Brand name used

Generic name

Price/28's tablet in AED

Diovan 80 mg
Concor 2.5 mg
Lasix 40 mg
Aldactone 25 mg
Norvasc 5 mg
Concor 5 mg
Coaprovel 300/25 mg
Twynsta 80/10 mg
Physiotens 0.4 mg
Concor plus 5/12.5 mg
Micardis 80/12.5 mg
Norvasc 10 mg
Triplixam 10/2.5/10 mg
Tenormin 50 mg
Micardis 80/25 mg
Zestoretic 20/12.5 mg
Hyzaar 50/12.5 mg
Triplixam 5/1.25/5 mg
Dilatrend 6.25 mg
Coveram 10/10 mg
CoDiovan 160/12.5 mg
Esidrex 25 mg
CoAprovel 300/12.5 mg
Coversyl 5 mg
Aprovel 150 mg
Zestril 5 mg
Nebilet 5 mg
Fortzaar 100/25 mg
Coveram 5/10 mg
Twynsta 80/5 mg
Atacand 16 mg
Coveram 5/5 mg
Coveram 10/5 mg
Atacand 4 mg
Zestril 10 mg
Aprovel 300 mg
Bipreterax 5/1.25 mg
Concor 10 mg
Micardis 40 mg
Tritace 10 mg
Coversyl 10 mg

Valsartan
Bisoprolol
Furosemide
Spironolactone
Amlodipine
Bisoprolol
Irbesartan/Hydrochlorothiazide
Telmisartan/Amlodipine
Moxonidine
Bisoprolol/Hydrochlorothiazide
Telmisartan/Hydrochlorothiazide
Amlodipine
Perindopril/Indapamide/Amlodipine
Atenolol
Telmisartan/Hydrochlorothiazide
lisinopril/Hydrochlorothiazide
Losartan/Hydrochlorothiazide
Perindopril/Indapamide/Amlodipine
Carvedilol
Perindopril/Amlodipine
Valsartan/Hydrochlorothiazide
Hydrochlorothiazide
Irbesartan/Hydrochlorothiazide
Perindopril
Irbesartan
Lisinopril
Nebivolol
losartan/hydrochlorothiazide
Perindopril/Amlodipin
Telmisartan/Amlodipine
Candesartan
Perindopril/Amlodipine
Perindopril/Amlodipine
Candesartan
Lisinopril
Irbesartan
Perindopril/Indapamide
Bisoprolol
Telmisartan
Ramipril
Perindopril

138
23.5
20
19
89
34
126.5
147
72
36.5
125
178
199
29.5
109.5
90.5
88.5
188.5
28
162
156
14.5
126.5
80
99.5
29.5
73.5
88.5
152.5
147
92.5
151
156
63.5
66
117
90
45.5
97
118
123.5

The average cost increase in AED for each class:
Angiotensin converting enzyme inhibitor (ACEI):
Angiotensin receptor blocker (ARB)
Diuretics (D)
Calcium channel blocker (CCB)
Beta blocker
Combination ACEI þ CCB
Combination ARB þ D
Combination ARB þ CCB
Combination ACEI þ CCB þ D

non-pharmacological intervention with or without
mono-antihypertensive therapy. Of whom, 136 patients (34%) had diabetes mellitus, and/or estimated
10 years CVD risk more than 10% and/or chronic
kidney disease and they were advised to receive
non-pharmacological and pharmacological treatment. Contrarily, those who had estimated 10 years
CVD risk score less than 10%, no diabetes and no

83.4
101.25
17.83
133.5
39
155.38
117.22
147
193.75

chronic kidney disease (n ¼ 108; counted for 27%)
were advised to receive a non-pharmacological interventions as initial strategy(Table 5).
Therefore, out of the 244 patients, at least additional 70 patients will need antihypertensive
regimen according to the new guidelines (66 patients already treated and 108 are recommended for
non-pharmacological interventions as initial
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Table 3. Demographic, clinical characteristics and proportions of those with no prior diagnosis of hypertension based on their BP level.
BP Categories (n ¼ 194)
Total participants
Population characteristics
Age:
Gender:
Male
Female
Smoking
SBP, mmHg
DBP, mmHg
Total cholesterol
HDL
LDL
Dyslipidemia and on statin
Diabetes and on diabetic medications
Albuminuria
eGFR:
BMI:
Mean of estimated 10 years risk of CVDa:
<5%
5% - < 10%
10%
History of CVD
a

Total

<120/<80

120-129/<80

130-139/80-89

140-159/90-99

160/100

28 (14.4%)

14 (7.2%)

142 (73.2%)

6 (3.1%)

4 (2.1%)

40.4 ± 13.2

45.4 ± 14.9

46.2 ± 10.4

53 ± 2.6

56 ± 2.8

2 (1%)
26 (13.4%)
4 (2.1%)
111.5 ± 6.1
71.6 ± 5.4
168.2 ± 37.9
46.8 ± 10.3
107.1 ± 39.4
4 (2.1%)
2 (1%)
4 (2.1%)
96.2 ± 25.7
26.9 ± 5.1
1.97 ± 1.5
26 (13.4%)
0
0
2 (1%)

6 (3.1%)
8 (4.1%)
4 (2.1%)
122.4 ± 2.6
72.1 ± 5.2
195.1 ± 44.3
46.1 ± 9.1
116.1 ± 27.8
0
2 (1%)
4 (2.1%)
91.1 ± 28.9
27.5 ± 4.6
5.08 ± 4.9
8 (4.1%)
4 (2%)
2 (1%)
0

92 (47.4%)
50 (25.8%)
52 (26.8%)
128.4 ± 7.8
83.7 ± 2.9
193.4 ± 40.8
41.7 ± 9.5
124.2 ± 36.1
32 (16.5%)
60 (30.9%)
10 (5.2%)
95.9 ± 16.4
29.1 ± 5.2
7.72 ± 5.2
68 (35.1%)
34 (17.5%)
40 (20.6%)
0

2 (1%)
4 (2.1%)
2 (1%)
144.3 ± 1.9
89.3 ± 6.5
160.3 ± 13.3
38.1 ± 3.6
88.3 ± 16.1
4 (2.1%)
6 (3.1%)
2 (1%)
85.1 ± 15.3
32.4 ± 7.5
8.96 ± 6.4
2 (1%)
2 (1%)
2 (1%)
0

4 (2.1%)
0
2 (1%)
151 ± 7.0
100 ± 1.1
160 ± 46.6
38.2 ± 5.6
100.5 ± 48.7
4 (2.1%)
4 (2.1%)
1 (0.5%)
87.5 ± 23.3
26.4 ± 3.3
21.9 ± 17.5
0
2 (1%)
2 (1%)
0

194 (48.5%)

106 (54.7%)
88 (45.3%)
64 (32.9%)

44 (22.6%)
74 (38.1%)
21 (10.8%)

104 (53.7%)
42 (21.6%)
46 (23.7%)
2 (1%)

Mean risk is calculated among the participants without history of CVD.

Table 4. Demographic, clinical characteristics and proportions of those with history of hypertension based on their BP level.
BP Categories (n ¼ 206)
Total participants
Population characteristics
Age:
Gender:
Male
Female
Smoking
SBP, mmHg
DBP, mmHg
Total cholesterol
HDL
LDL
Dyslipidemia and on statin
Diabetes and on diabetic medications
Albuminuria
eGFR:
BMI:
Mean of estimated
10 years risk of CVDa:
<5%
5% - < 10%
10%
History of CVD
On non-pharmacological intervention
On non-pharmacological
intervention and antihypertensive
medication
a

Total

<120/<80

120-129/<80

130-139/80-89

140-159/90-99

160/100

12 (5.8%)

10 (4.8%)

120 (58.2%)

48 (23.3%)

16 (7.7%)

56.8 ± 10.9

50.8 ± 11.3

51.4 ± 10.6

59.5 ± 12.6

50.3 ± 8.3

8 (3.9%)
4 (1.9%)
6 (2.9%)
111.8 ± 6.1
69.8 ± 6.9
180.5 ± 53.03
34.8 ± 12.7
112.1 ± 34.4
6 (2.9%)
4 (1.9%)
2 (0.9%)
83.8 ± 9.1
29.6 ± 3.4
13.2 ± 4.4

10 (4.8%)
0
2 (0.9%)
123.2 ± 3.2
78.4 ± 6.1
175.2 ± 50.7
37.7 ± 7.7
118.4 ± 39.7
8 (3.9%)
8 (3.9%)
3 (1.5%)
87.6 ± 30.6
31.3 ± 6.1
11.3 ± 4.2

72 (34.9%)
48 (23.3%)
32 (15.5%)
131.4 ± 7.2
82.3 ± 4.9
200.2 ± 49.5
41.1 ± 8.7
125.6 ± 39.5
78 (37.8%)
74 (35.9%)
12 (5.8%)
90.7 ± 23.1
31.6 ± 7.01
13.3 ± 10.4

30 (14.5%)
18 (8.7%)
18 (8.7%)
145.5 ± 6.9
82.9 ± 10.7
183.04 ± 34.6
39.2 ± 10.3
120.2 ± 28.5
30 (14.6%)
32 (15.5%)
15 (7.3%)
75.8 ± 26.5
30.1 ± 7.3
22.3 ± 12.3

12 (5.8%)
4 (1.9%)
6 (2.9%)
160.2 ± 10.5
99.1 ± 5.1
193.4 ± 46.4
42.1 ± 9.1
124.1 ± 35.1
6 (2.9%)
4 (1.9%)
10 (4.9%)
91.8 ± 13.4
27.1 ± 2.8
14.4 ± 8.6

132 (64.1%)
74 (35.9%)
64 (31.1%)

0
4 (1.9%)
0
8 (3.9%)
2 (0.9%)
10 (11.7%)

0
2 (0.9%)
4 (1.9%)
4 (1.9%)
0
10 (11.7%)

30
16
50
24
22
98

4 (1.9%)
6 (2.9%)
28 (13.6%)
10 (11.7%)
12 (5.8%)
36 (17.5%)

2 (0.9%)
2 (0.9%)
8 (3.9%)
4 (1.9%)
0
16 (7.8%)

36 (17.5%)
30 (14.6%)
90 (43.7%)
50 (24.2%)
36 (17.5%)
170 (82.5%)

Mean risk is calculated among the participants without history of CVD.

(14.6%)
(7.8%)
(24.2%)
(11.6%)
(10.7%)
(47.5%)

206 (51.5%)

128 (62.1%)
122 (59.2%)
42 (20.4%)

104 (28.1%)

3.3. The proportions of patients who had abovegoal BP according to the two sets of guidelines

3.4. Cost Implication of Applying the 2017-ACC/
AHA guideline
*NPI: non-pharmacological intervention.
**All percentages are within the total number of patients.

36 (10.0%)

66 (18.4%)

104 (29.0%)

According to JNC-8 guideline 31.5% (n ¼ 68) of the
patients had above the BP target, compared to 93.8%
(n ¼ 336) of the patients had above-target BP according to the 2017-ACC/AHA guideline (Table 5).
Of whom, 29.6% (n ¼ 106) are recommended for
non-pharmacological intervention as initial strategy.
On the other hand, seventy patients are not
receiving medications and need monotherapy as
indicated above. A combination medications are
recommended for those who did not meet the target
and already receiving antihypertensive (n ¼ 160); 60
patients from stage 1 and 100 patients from stage 2
(Table 5). There is a signiﬁcant increase in the proportion of patients who had above goal BP based on
the ACC/AHA guideline compare to the JNC-8
guideline X2(df ¼ 1) ¼ 251.4, p ¼ 0.0001.

Based on the calculation in Tables 1 and 2, the cost
of medications would be increased by approximately 4585 AED per month [70*65.5 AED] and
55,020 AED per year for those who were newly
labeled as hypertensive patients (n ¼ 70) and recommended to start antihypertensive medications
according to the 2017-ACC/AHA guideline.
Additionally, the cost would be increased by
almost [160*65.5AED ¼ 10,480 AED per month]
(125,760 AED per year) for those who advised for
intensive therapy (n ¼ 160) to meet the goal according to 2017-ACC/AHA guideline.
3.5. Extrapolation of results to UAE population
Figure 1 shows the summary of the comparison
between the 2017-ACC/AHA and JNC-8 guidelines
regarding the extrapolated number of UAE adults'
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strategy). Those on non-pharmacological interventions (n ¼ 108) will also likely require treatment in the future.
Based on the 2017-ACC/AHA guideline 114
(28.5%) patients were labeled as stage 2 hypertension and advised for combination antihypertensive
therapy. While, only 108 (27%) patients were labeled
as stage 2 hypertension according to JNC-8 guidelines (Table 5).
There is a signiﬁcant difference in number of patients recommended for antihypertensive medications between the two sets of the guidelines
X2(df ¼ 1) ¼ 9.08, p ¼ 0.003.

66 (30.6%)

38(17.6%)
50 (22.1%)

59 (16.5%)

66 (30.6%)
6 (1.7%)
136 (38%)

6 (1.7%)

24 (11.2%)
4 (1.8%)
42 (19.5%)
2 (0.55%)
108 (30.2%)

136 (34%)
108 (27%)

No. of patients (%)
Type of intervention:
On non-pharmacological
intervention (NPI)
On 1 antihypertension
class þ NPI
On 2 antihypertension
classes þ NPI
On 3 or more
classes þ NPI
Concordance with
guidelines

55 (15.3%)

148 (68.5%)
108 (27%)
108 (27%)
22 (6.2%)
114 (25.5%)

56 (25.9%)

Met the
target
Stage 2 hypertension
(require combination
drug therapy)
Stage 1 hypertension
(lifestyle modiﬁcation
and drug therapy)
Met the
target
Stage 2 hypertension
(require combination
drug therapy)
Stage 1 hypertension
(lifestyle modiﬁcation
and drug therapy)

2017-ACC/AHA guideline (n ¼ 358, 89.5%)

Stage 1 hypertension
(lifestyle modiﬁcation)

Participants who met the deﬁnition according to the 2017-ACC/AHA guideline in comparison with JNC-8 guideline

Table 5. Blood pressure control according to the 2017-ACC/AHA guideline in comparison with JNC-8 guideline (n ¼ 400).

JNC-8 guideline (n ¼ 216, 54%)
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Fig. 1. Summary of the comparison between the 2017-ACC/AHA and JNC-8 guidelines regarding the extrapolated number and percentage of UAE
adults population who met the deﬁnition of hypertension, number and percentage of UAE adults population recommended for antihypertensive
medications and number and percentage of hypertensive patients who had BP above target. The data are present in million (n ¼ 7.54 millions).

population who would meet the deﬁnition of hypertension, number of UAE adults’ population who
would be recommended for antihypertensive medications and number of hypertensive patients who
would have BP above target.
Accordingly, 5.75 (76.3% of 7.54 million adult)
million UAE adults would meet the criteria for hypertension according to 2017-ACC/AHA guideline
compared with 3.07 (40.8%) million UAE adults met
the deﬁnition of JNC-8 guideline (see method section). Of whom, 4.71 (62.5%) million UAE adults
would be recommended to use antihypertensive
medications in addition to non-pharmacological
intervention. Whereas, 1.04 (13.8%) million would
meet the criteria for treatment with non-pharmacological interventions. An additional 2.29 (30.4%)
million UAE adults would be recommended for
antihypertensive medication according to the 2017ACC/AHA guideline in comparison with the JNC-8
guideline.
Furthermore, Among UAE adults who are recommended to use antihypertensive medications,
4.42 (58.6% of UAE adults, N ¼ 7.54 millions) million
would have BP above the target according to the
2017-ACC/AHA guideline whereas 0.76 (10.1% of
UAE adults, N ¼ 7.54 millions) million would have

BP above the target according to the JNC-8
guideline.
The expected increase in the cost of antihypertension medications prescribed for the new
labeled cases (n ¼ 2.29 million) that need pharmacological treatment in UAE according to ACC/AHA
guideline but not JNC-8 would reach 149.99 million
AED per month (1.8 billion AED/year). For those
who were recommended for antihypertensive
medications according to ACC/AHA guideline, who
had BP above the target (N ¼ 4.42 million), the cost
would approximately reach 289.51 million AED per
month (3.5 billion AED/year) for additional medications to control blood pressure. While, it would
cost only 49.78 million AED per month (597.36
million AED per year) (N ¼ 0.76 millions) according
to the 2014 JNC-8 guideline.
3.6. Adherence of physicians to the 2017-ACC/
AHA guideline recommendations
Among all participants, 57.4% (n ¼ 206) of the
patients were in concordance with the 2017-ACC/
AHA guideline recommendations. Of whom, 10%
(n ¼ 36) were on non-pharmacological intervention.
While, 47.4% (n ¼ 170) were on antihypertensive

medications. Contrarily, 78.7% (n ¼ 170) of the patients were in consistency with the JNC-8 guideline.
Of whom, 30.6% (n ¼ 66) were on non-pharmacological with or without mono-antihypertensive
treatment. While, 48.1% (n ¼ 104) were on intensive
antihypertensive medications. Based on that, the
compliance with the JNC-8 was signiﬁcantly higher
reﬂecting greater physicians’ adherence with it
(Table 5).

4. Discussion
Based on this study, the proportion of patients
with hypertension was increased by 65.7% according to the 2017-ACC/AHA guideline; half of them
were advised to be treated with pharmacological
therapy. This study showed high percentage (93.8%)
of the patients who had above-goal BP according to
the 2017-ACC/AHA compared to JNC-8 guidelines
(31.5%), which in turn reﬂected the poor compliance
of the physicians with the new guidelines. The
reasons behind this are that the guideline was still
recent and physicians were hesitant to apply the
new recommendations and use antihypertensive for
lower blood pressure values. In comparison,
Muntner P et al. (2018) demonstrated a notable increase in the prevalence of hypertension (13.7%)
and a small increase in the percentage of US adults
who were recommended for antihypertensive
medications (1.9%) according to the 2017-ACC/AHA
guideline compared with the JNC-7 guideline. In
the same study, 14.4% of US adults taking antihypertensive medication had a BP above the goal
deﬁned by the 2017-ACC/AHA guideline, whereas
they would have met the BP goal according to the
JNC-7 guideline [3].
The majority of hypertensive patients (68.5%) had
well-controlled blood pressure and most of those
patients were on 2 or more antihypertensive medications according to JNC-8 guideline. While, if the
recommendation of the 2017-ACC/AHA guideline
has to be followed then the number of hypertensive
patients who had well-controlled blood pressure
will dramatically drop to (6.2%) which necessitates
adding additional antihypertensive medication to
the patients’ treatment plan.
The study results indicate that the 2017-ACC/
AHA guideline recommend much more aggressive
therapy. However, the incidence of adverse events
was higher in the intensive treatment group like
hypotension, syncope, electrolyte disturbance,
injurious fall and acute renal failure [16e18].
Although, several studies had reported risk reduction of coronary heart disease (CHD), stroke mortality and end stage renal disease with lower BP
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levels than that in the guidelines [19e22]. However,
Shen L et al. (2013) illustrated that the efﬁcacy of BP
reduction in subjects was not clariﬁed [20].
Other studies reported that treatment of prehypertension with antihypertensive medications
particularly the angiotensin converting enzyme inhibitor (ramipril), angiotensin receptor blocker
(candesartan), low dose chlorthalidone and amiloride were well tolerated and reduced the risk of
incident of stage 1 hypertension [23e25]. Additionally, in patients with pre-existing coronary artery
disease (CAD), hypertension or left ventricular hypertrophy (LVH), a J-curve effect had been observed
between a diastolic BP of 70e80 mmHg as well as a
systolic BP less than 130 mmHg “The J-curve effect
describes an inverse relation between low blood
pressure (BP) and cardiovascular complications”
[26].
While the ACCORD study that was conducted by
Cushman W et al. (2010) in patient with type 2
diabetes at higher risk for cardiovascular events,
reducing the SBP to less than 120 compared to less
than 140 was not associated with reduction in the
outcome of fatal and nonfatal major cardiovascular
events [27]. Moise N et al. (2016) illustrated that
adding intensive goals for high risk patients
remained consistently cost effective in men, but not
in women [28].
The National Institute for Health and Care
Excellence (Nice) has estimated the number of patients advised to take pills for early signs of high
blood pressure will be tripled under the new guidance of the 2017-ACC/AHA guidelines [29].
The new target goals and the use of ASCVD risk
score in the deﬁnition of stage 1 and 2 hypertension
would substantially increase the number of hypertensive patients in the population. On the other
hand, such changes will lead to more pharmacologic
interventions and more aggressive therapy to achieve the lower blood pressure targets and that, will
be accompanied by considerable adverse events,
discontinuation and possibly reduction in patients’
quality of life. Such issues should not be masked by
the overwhelming beneﬁts [6,30e33]. Giving these
factors and the substantial increase in the number of
patients who would require antihypertensive, the
long-term impact should be the goal of future
studies in the UAE.
This study had several strengths; the study was
conducted after the implication of the 2017-ACC/
AHA guideline where the compliance of the physicians with this guideline could be evaluated. The
measurement of BP was done on several visits with
ﬁxed approach of BP measurement which reﬂected
higher accuracy. It highlighted the differences
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between 2017-ACC/AHA and JNC-8 guidelines and
estimated the expected cost resulted from applying
such guidelines.
4.1. Study limitations
One of the limitations of this study is that it is
conducted in one study site. However, in order to
maximize study generalizability, we screened all
patients admitted to the study site during the study
period and included all eligible patients. On the
other hand, demographic characteristics are similar
to those reported in studies investigating cardiovascular disease in UAE taking into account that we
screened patients attending outpatients’ clinic.
Therefore, we expect the study sample to be similar
to the UAE population.

5. Conclusions
The adherence with the 2017-ACC/AHA guideline
would markedly increase the proportion of hypertension in the UAE adults’ population. The percentage of UAE adults recommended for lifestyle
modiﬁcation as a ﬁrst line for management of hypertension would considerably rise. The recommendation for anti-hypertension medications in
addition to non-pharmacological interventions
would substantially increase and signiﬁcantly increase the cost of medications.
The study also reveals poor compliance with the
2017-ACC/AHA, which may be due to the concern
regarding the increase risk of adverse events with
more aggressive pharmacological therapy.
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